Investigating visual pathways in multiple sclerosis
Evaluation of Neuroaxonal Loss Outside of Any Inflammation in Multiple Sclerosis by a Multimodal Study of the Visual Pathways Model
NA · University Hospital, Lille · NCT06776224
This study is trying to understand how multiple sclerosis affects vision and brain function by looking at changes in the eyes and how they relate to the disease over time.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Lille (other) |
| Locations | 1 site (Lille) |
| Trial ID | NCT06776224 on ClinicalTrials.gov |
What this trial studies
This study focuses on understanding the mechanisms behind neurodegenerative processes and visual impairment in patients with multiple sclerosis (MS). It employs a longitudinal multimodal analysis of visual pathways, including measurements of retinal vascular density and visual cognition. The research aims to elucidate the relationship between acute demyelinating lesions and both immediate and delayed axonal loss in MS. Participants will be monitored over time to assess changes in visual function and cognition.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with relapsing-remitting multiple sclerosis who are receiving treatment and have previously participated in the VWIMS study.
Not a fit: Patients under 18 years old or those with other neurological conditions that could interfere with the study's data collection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of visual impairments in multiple sclerosis patients.
How similar studies have performed: Other studies have explored similar approaches in understanding visual impairment in multiple sclerosis, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Patients with relapsing-remitting multiple sclerosis receiving high-efficacy or non-high-efficacy treatment and follow-up at the CRCSEP of the Lille University Hospital through past participation in the VWIMS study. Inclusion criteria: * Male and/or female participants in the VWIMS research project * At least 18 years of age at the time of inclusion in VWIMS - II * Patient having given written consent to participate in the study * Socially insured patient * Patient willing to comply with all study procedures and duration Exclusion Criteria: * Age \< 18 years * Other neurological pathologies that may interfere with MRI and/or OCT data (diabetes, retinopathy \[any cause\], glaucoma, retinal detachment, ametropia \> 6 diopters) * Contraindications to MRI (claustrophobia, incompatible metal foreign bodies such as certain pacemakers and mechanical valves, cochlear implants, intra-orbital metal splinters, pregnancy, certain brands of IUD because of the 3 Tesla magnetic field). * Contraindication to injection: severe renal failure with creatine clearance \<30, allergy to contrast media, pregnancy, breast-feeding. * Pregnant women * Nursing women * Persons incapable of giving consent on their own, with or without legal protection (guardianship/curatorship) * Person under legal protection * Persons deprived of their liberty * Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign consent form
Where this trial is running
Lille
- Direction de la Recherche et de l'innovation (DRI) 6 rue Professeur Laguesse — Lille, France (RECRUITING)
Study contacts
- Study coordinator: OUTTERYCK Olivier, PhD
- Email: olivier.outteryck@chru-lille.fr
- Phone: 03.20.44.64.69
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Sclerosis, Optic Neuritis, Demyelinating Disease, Multiple sclerosis, cognition, OCT, MRI, visual impairment